Suppr超能文献

苯妥英治疗所致骨病:临床与实验研究

Bone disease induced by phenytoin therapy: clinical and experimental study.

作者信息

Moro-Alvarez M J, Díaz Curiel M, de la Piedra C, Mariñoso M L, Carrascal M T

机构信息

Internal Medicine, Metabolic Bone Disease Unit H, Central Cruz Roja, Madrid, Spain.

出版信息

Eur Neurol. 2009;62(4):219-30. doi: 10.1159/000229309. Epub 2009 Jul 23.

Abstract

Previous studies have made references to prolonged treatment with phenytoin as a possible risk factor in the development of osteoporosis and/or osteomalacia. We studied a group of 30 epileptic patients who were under long-term treatment with phenytoin (DPH) in an ambulatory regimen. We found the prevalence of osteoporosis to be 3.3% and of osteopenia to be 56.6%, affecting predominantly the femur, without any significant decrease in bone mineral density of the lumbar spine. These patients were showing signs of bone turnover uncoupling with increases in bone resorption markers. At this time, they also exhibited slight alterations in their phosphocalcium metabolism with trends to hypocalcemia and secondary hyperparathyroidism that was found not to be caused by a vitamin D deficiency as the serum levels of 25(OH)D and 1,25(OH)(2)D were normal. With the aims of corroborating these results and to investigate the physiopathological effects on the bone induced by anticonvulsant drugs we developed a further experimental study in which we administered DPH over a 6-week period with a dose of 5 g/kg/day to male Wistar rats that were in the growth phase. This treatment produced a decrease in overall BMD and bone mineral content in the femur. We did not find osteomalacia in the vertebral biopsy, but the administration of DPH to these animals decreased trabecular volume as well as lessened the thickness of osteoid edges together with an uncoupling in bone turnover. There was also a marked decrease in bone formation and a tendency towards increased bone resorption. We have also found a decrease in resistance to fracture by torsion in the biomechanical assay, which translates into an increase in bone fragility. In these male Wistar rats, the administration of DPH produced a tendency towards increasing the markers of resorption and, though changes in serum levels of calcium and phosphorus were not observed, to provoke an increase in the parathyroid hormone levels; with normal levels of 1,25(OH)(2)D which has produced the same inclination in rats as in humans.

摘要

以往的研究提到,长期使用苯妥英钠治疗可能是骨质疏松症和/或骨软化症发生的一个风险因素。我们研究了一组30例癫痫患者,他们正在接受苯妥英钠(DPH)的门诊长期治疗。我们发现骨质疏松症的患病率为3.3%,骨质减少的患病率为56.6%,主要影响股骨,而腰椎骨矿物质密度没有任何显著降低。这些患者表现出骨转换解偶联的迹象,骨吸收标志物增加。此时,他们的磷钙代谢也出现了轻微改变,有低钙血症和继发性甲状旁腺功能亢进的趋势,发现这并非由维生素D缺乏引起,因为血清25(OH)D和1,25(OH)₂D水平正常。为了证实这些结果并研究抗惊厥药物对骨骼的生理病理影响,我们开展了进一步的实验研究,给处于生长阶段的雄性Wistar大鼠连续6周每天给予5 g/kg的DPH剂量。这种治疗导致股骨的总体骨密度和骨矿物质含量下降。我们在椎体活检中未发现骨软化症,但给这些动物使用DPH会减少骨小梁体积,同时减少类骨质边缘的厚度,并导致骨转换解偶联。骨形成也有明显减少,骨吸收有增加的趋势。我们还发现在生物力学试验中,扭转骨折抵抗力下降,这意味着骨脆性增加。在这些雄性Wistar大鼠中,使用DPH会导致吸收标志物有增加的趋势,虽然未观察到血清钙和磷水平的变化,但会导致甲状旁腺激素水平升高;1,25(OH)₂D水平正常,这在大鼠中产生了与人类相同的倾向。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验